Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01887353 · ClinicalTrials.gov registry record · Phase 2
The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure
A Phase 2 study, sponsored by Intermountain Health Care.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT01887353 is a Phase 2 study that was terminated before completion, run by Intermountain Health Care. The registered enrollment target is 8 participants.
The verdict
NCT01887353, a Phase 2 study, was terminated before completion, sponsored by Intermountain Health Care.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.
Interventions
- DRUG Placebo
- DRUG Ranolazine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01887353
The ClinicalTrials.gov registry entry for NCT01887353 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01887353 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01887353 about?
NCT01887353 is a clinical study titled "The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure". The purpose of this study is to evaluate the efficacy of ranolazine in the prevention of recurrent atrial fibrillation in post-cardioversion patients with heart failure and preserved ejection fraction.
What is the current status of trial NCT01887353?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2013-06. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01887353?
The interventions under investigation include: Placebo (DRUG), Ranolazine (DRUG).
Who is sponsoring clinical trial NCT01887353?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.